Search Medical Condition
Please enter condition
Please choose location

Kinki, Japan Clinical Trials

A listing of Kinki, Japan clinical trials actively recruiting patients volunteers.

RESULTS

Found (166) clinical trials

Early Infectious Disease Consultations in Staphylococcus Aureus Bacteremia

Bacteremia is a serious manifestation of Staphylococcus aureus infection with an attributable mortality as high as 25% in MRSA bacteremia. More than a third of patients end up with complications such as endocarditis, osteomyelitis or pneumonia. Overall the outcome of patients with respect to mortality or recurrence is better in ...

Phase N/A

0.75 miles

Learn More »

Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)

This trial will enroll approximately 6,000 patients with recent embolic stroke of unknown source (ESUS). Patients will be randomized to dabigatran or acetylsalicyclic acid (ASA) (1:1 ratio) and have visits every three months. The study doctor may prescribe blinded concomitant ASA for pts with coronary artery disease but this is ...

Phase

1.0 miles

Learn More »

32P BioSiliconTM in Addition to Gemcitabine in Pancreatic Cancer

This will be an open label, Phase IIa safety study recruiting about 15 patients from at least two sites. All patients will have 32P BioSilicon implanted into the pancreatic tumour as a single implant, using endoscopic ultrasound. The study will examine the safety of an injected activity equivalent to an ...

Phase

1.14 miles

Learn More »

Combination Chemotherapy and Interferon Alfa-2b in Treating Patients With Nonmetastatic Liver Cancer That Cannot Be Removed by Surgery

OBJECTIVES: Primary - Determine the response rate in patients with unresectable, nonmetastatic hepatocellular carcinoma treated with neoadjuvant oxaliplatin, doxorubicin hydrochloride, fluorouracil, and recombinant interferon alfa-2b. Secondary - Determine the overall survival of patients treated with this regimen. - Determine the progression-free survival of patients treated with this regimen. - Determine ...

Phase

1.15 miles

Learn More »

Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers

Aspirin in patients with dukes C or high risk dukes B colorectal cancer can improve survival in this patient population over placebo control. Eligible patients will be randomized to treatment arms, using the following stratification factors: - Study Centre - Tumour Type - Type of adjuvant chemotherapy received(exposed/not exposed to ...

Phase

1.15 miles

Learn More »

Cyclophosphamide Methotrexate and Prednisolone With or Without Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer

OBJECTIVES: Primary - Compare the clinical benefit rate (complete response, partial response or stable disease for > 24 weeks) in postmenopausal women with metastatic breast cancer treated with metronomic chemotherapy with vs without aromatase inhibitor therapy. Secondary - Compare the time to progression in these patients - Compare the overall ...

Phase

1.15 miles

Learn More »

Gemcitabine and Carboplatin Followed By Laboratory-Treated T Lymphocytes in Treating Patients With Metastatic or Locally Recurrent Epstein-Barr Virus-Positive Nasopharyngeal Cancer

OBJECTIVES: Primary - To determine progression-free survival (PFS 1) of patients with metastatic or locally recurrent Epstein-Barr virus (EBV)-positive nasopharyngeal carcinoma treated with gemcitabine hydrochloride and carboplatin followed EBV-specific cytotoxic T-lymphocytes (CTL). Secondary - To determine progression-free survival (PFS 2) of these patients during the immunotherapy portion of this study. ...

Phase

1.15 miles

Learn More »

Cyclophosphamide and Docetaxel or Doxorubicin in Treating Women With Newly Diagnosed Breast Cancer That Can Be Removed by Surgery

OBJECTIVES: Primary - To evaluate tumor pathological complete response rate after neoadjuvant cyclophosphamide in combination with docetaxel vs doxorubicin hydrochloride in women with operable clinically node-negative breast cancer and normal topoisomerase IIα expression. Secondary - To assess tumor clinical and pathological overall response rates in patients treated with these regimens. ...

Phase

1.15 miles

Learn More »

Combination Therapy With NC-6004 and Gemcitabine Versus Gemcitabine Alone in Pancreatic Cancer

Pancreatic cancer is one of the most deadly cancers because of the predominately late diagnosis. Gemcitabine (GEM) is the standard treatment for advanced and metastatic pancreatic cancer. According to preclinical data and few early phase studies, a combined use of gemcitabine and cisplatin (CDDP) showed synergistic efficacy against pancreatic cancer. ...

Phase

1.15 miles

Learn More »

A Phase I/II Multicenter Open-label Study of EGFRmut-TKI EGF816 Administered Orally in Adult Patients With EGFRmut Solid Malignancies

To estimate the maximum tolerated dose (MTD) or recommended phase II dose (RP2D) (Phase l part) of EGF816 and to investigate the anti-tumor activity of EGF816 (Phase II part).

Phase

1.15 miles

Learn More »